A 55-year-old man from Mumbai presents with painless cervical lymphadenopathy and hepatosplenomegaly. Biopsy shows diffuse infiltration of large atypical B lymphocytes with CD5+ immunophenotype. Which single feature best distinguishes this diagnosis (Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma) from Mantle Cell Lymphoma?

Question

Accepted Answer

B. CD23 positivity with low Ki-67 proliferation index. ## Distinguishing CLL/SLL from Mantle Cell Lymphoma

### Clinical Context

Both CLL/SLL and mantle cell lymphoma present with lymphadenopathy, hepatosplenomegaly, and a CD5+ B-cell phenotype. The challenge is distinguishing them using reliable pathologic features.

### Comparative Table

| Feature | CLL/SLL | Mantle Cell Lymphoma |
|---------|---------|----------------------|
| **CD5 expression** | Positive | Positive |
| **CD23 expression** | **Positive** | **Negative** |
| **Cytogenetics** | del(13q), del(11q), del(17p); NO t(11;14) | t(11;14) (95%) |
| **Cyclin D1** | Normal | Overexpressed |
| **Ki-67 index** | Low (<10%) | Intermediate to high (30–50%) |
| **Morphology** | Small, mature lymphocytes | Small to medium cells, nodular/diffuse |
| **Median survival** | 5–10 years (variable) | 3–5 years (poor prognosis) |
| **Age** | Elderly (median 70 years) | Older adults (median 60 years) |

### Why CD23 Positivity is the Gold Standard Discriminator

**Key Point:** The **CD5+/CD23+ immunophenotype is pathognomonic for CLL/SLL**, whereas mantle cell lymphoma is **CD5+/CD23−**. This single-parameter flow cytometry distinction is:

1. **Objective and reproducible** — flow cytometry is standardized across laboratories.
2. **Rapid** — results available within hours.
3. **Highly specific** — CD23 negativity in a CD5+ lymphoma strongly suggests mantle cell lymphoma.
4. **Part of WHO diagnostic criteria** for both entities.

**High-Yield:** The mnemonic **"CLL is CD5+/CD23+; MCL is CD5+/CD23−"** is essential for rapid diagnosis.

**Mnemonic:** **"CD5 is the CLOWN (CLL + Mantle Cell); CD23 is the CLUE (CLL Only)"** — CD23 distinguishes CLL from MCL.

### Pathophysiology of CD23 Expression

**Clinical Pearl:** CD23 is a low-affinity IgE receptor and is upregulated by CD40-CD40L interaction and IL-4 signaling in CLL cells. In mantle cell lymphoma, the t(11;14) translocation drives cyclin D1 overexpression, which suppresses CD23 transcription, resulting in CD23 negativity.

### Why Other Features Are Not Discriminators

**Warning:** 
- **t(11;14) and cyclin D1** are specific to mantle cell lymphoma but require FISH or immunohistochemistry — slower and more expensive than flow cytometry.
- **Nodal involvement and splenomegaly** occur in both diseases.
- **CD5+ and CD19+ phenotype** are shared by both CLL/SLL and mantle cell lymphoma — not discriminatory.
- **Ki-67 index** is helpful but overlaps and requires quantitative assessment, less practical than CD23 flow cytometry.

### Diagnostic Algorithm

```mermaid
flowchart TD
  A[CD5+ B-cell lymphoma]:::outcome --> B{CD23 positive?}:::decision
  B -->|Yes| C[CLL/SLL]:::outcome
  B -->|No| D{t(11;14) or cyclin D1+?}:::decision
  D -->|Yes| E[Mantle Cell Lymphoma]:::outcome
  D -->|No| F[Other lymphoma]:::outcome
  C --> G[Low Ki-67, indolent course]:::action
  E --> H[Higher Ki-67, aggressive course]:::urgent
```

Answer

A. Nodal involvement with splenomegaly

Answer

C. CD5+ B-cell phenotype with CD19 expression

Answer

D. t(11;14) translocation with cyclin D1 overexpression

Explanation

Distinguishing CLL/SLL from Mantle Cell Lymphoma

Clinical Context

Comparative Table

Why CD23 Positivity is the Gold Standard Discriminator

Pathophysiology of CD23 Expression

Why Other Features Are Not Discriminators

Diagnostic Algorithm

Practice similar questions

Join our NEET PG community

Feature	CLL/SLL	Mantle Cell Lymphoma
CD5 expression	Positive	Positive
CD23 expression	Positive	Negative
Cytogenetics	del(13q), del(11q), del(17p); NO t(11;14)	t(11;14) (95%)
Cyclin D1	Normal	Overexpressed
Ki-67 index	Low (<10%)	Intermediate to high (30–50%)
Morphology	Small, mature lymphocytes	Small to medium cells, nodular/diffuse
Median survival	5–10 years (variable)	3–5 years (poor prognosis)
Age	Elderly (median 70 years)	Older adults (median 60 years)